BiotechTube

Diclofenac Sodium Topical Gel, 1% + Voltaren Topical Gel, 1% + Vehicle Diclofenac Sodium Topical Gel

Phase 3Completed
1 views this week 0 watching💤 Quiet
Interest: 37/100
37
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
✓
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Osteoarthritis

Conditions

Osteoarthritis

Trial Timeline

Apr 1, 2014 → Dec 1, 2014

NCT ID
NCT02121002

About Diclofenac Sodium Topical Gel, 1% + Voltaren Topical Gel, 1% + Vehicle Diclofenac Sodium Topical Gel

Diclofenac Sodium Topical Gel, 1% + Voltaren Topical Gel, 1% + Vehicle Diclofenac Sodium Topical Gel is a phase 3 stage product being developed by Amneal Pharmaceuticals for Osteoarthritis. The current trial status is completed. This product is registered under clinical trial identifier NCT02121002. Target conditions include Osteoarthritis.

What happened to similar drugs?

20 of 20 similar drugs in Osteoarthritis were approved

Approved (20) Terminated (1) Active (0)
✅NISEDr. Reddy's LaboratoriesApproved
✅Duloxetine + Sugar pillEli LillyApproved
✅Capsaicin Topical SolutionAstellas PharmaApproved
✅duloxetineEli LillyApproved
✅ImrecoxibJiangsu Hengrui MedicineApproved
✅Etoricoxib (Arcoxia) + Sugar pillMerckApproved
✅zoledronic acidNovartisApproved

Hype Score Breakdown

Clinical
17
Activity
8
Company
12
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT02121002Phase 3Completed

Competing Products

20 competing products in Osteoarthritis

See all competitors
ProductCompanyStageHype Score
NISEDr. Reddy's LaboratoriesApproved
40
NISELATDr. Reddy's LaboratoriesPre-clinical
23
Duloxetine + PlaceboEli LillyPhase 3
40
LY2828360 + PlaceboEli LillyPhase 2
35
Investigational Medical Product (IMP) administered in parent studyEli LillyPhase 3
40
Duloxetine + Sugar pillEli LillyApproved
43
UBX0101 or placeboUnity BiotechnologyPre-clinical
8
UBX0101Unity BiotechnologyPhase 1
19
UBX0101Unity BiotechnologyPhase 2
25
UBX0101Unity BiotechnologyPhase 1
19
YH23537 + Celecoxib + YH23537 placeboYuhanPhase 2
35
Sodium hyaluronate + placebo injectionDaiichi SankyoPhase 3
32
ASP7962 + Naproxen + PlaceboAstellas PharmaPhase 2
35
Capsaicin Topical SolutionAstellas PharmaApproved
43
CGS-200-1 + CGS-200-5 + CGS-200 VehicleAstellas PharmaPhase 2
35
MM-II dose I + MM-II dose II + MM-II dose III + Placebo + Placebo + PlaceboSun PharmaceuticalPhase 2
35
Duloxetine + PlaceboShionogiPhase 3
40
DuloxetineShionogiPhase 3
40
ONO-4474 Part A1 + Placebo Part A1 + ONO-4474 Part A2 + Placebo Part A2 + ONO-4474 Part B + Placebo Part B + ONO-4474 Part C + Placebo Part C + ONO-4474 Part D + Placebo Part DOno PharmaceuticalPhase 1
29
ONO-4474 + Placebo matching ONO-4474Ono PharmaceuticalPhase 2
27